Photocure ASA: Presentation at the Carnegie Nordic Healthcare Day, New York
05. Dezember 2017 07:02 ET
|
Photocure ASA
Oslo, Norway, December 5, 2017 - Photocure ASA (OSE: PHO) announced today that the company will present at the Carnegie Nordic Healthcare Day, New York, on 5 December 2017. Presenter will be Ambaw...
Photocure ASA: Blue Light Flexible Cystoscopy with Cysview® Phase 3 study: New data presented at Society of Urological Oncology
01. Dezember 2017 02:32 ET
|
Photocure ASA
Oslo, Norway, December 1, 2017 Photocure ASA (OSE: PHO) announced today that more detailed data from the Phase 3 study data was presented at the prestigious Society of Urologic Oncology, Annual...
Photocure ASA: Clinical and cost impact analysis shows beneficial impact of replacing current surgical modalities with Cevira®
09. November 2017 06:55 ET
|
Photocure ASA
A poster demonstrating the clinical and cost impact of Cevira® was presented at the ISPOR European congress in Glasgow, Scotland, November 4-8, 2017. The budget impact model from a US payer...
Photocure ASA: Results for the third quarter of 2017
08. November 2017 01:15 ET
|
Photocure ASA
Oslo, Norway, 7 November 2017: Photocure ASA (OSE:PHO), today reported a revenue growth of 45% for the important US market in the third quarter of 2017, contributing to Hexvix/Cysview revenues of...
Photocure ASA:U.S. CMS improves reimbursement for Blue Light Cystoscopy with Cysview®
02. November 2017 03:07 ET
|
Photocure ASA
Oslo, Norway, November 2,2017: Photocure ASA (OSE: PHO), announced today that the United States Centers for Medicare & Medicaid Services (CMS) has issued a Final Rule stating that it will...
Photocure ASA: Presentation of the third quarter 2017 results
31. Oktober 2017 06:08 ET
|
Photocure ASA
Photocure will present its third quarter report on Wednesday 8 November 2017 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will...
Photocure ASA: BLC(TM) with Cysview®/Hexvix® real World Data presented at the Société Internationale d'Urologie 2017 Annual meeting
23. Oktober 2017 06:01 ET
|
Photocure ASA
Oslo, Norway, October 23, 2017 Photocure ASA announced that new data from the Blue Light Cystoscopy (BLC(TM)) with Cysview®/Hexvix® registry study were presented at the 37th Société Internationale...
Photocure ASA: FDA grants priority review for Cysview® supplemental New Drug Application (sNDA)
18. Oktober 2017 02:15 ET
|
Photocure ASA
Oslo, Norway, October 18, Photocure ASA (OSE: PHO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Cysview® on a...
Photocure ASA: Results for second quarter and first half year of 2017
23. August 2017 01:12 ET
|
Photocure ASA
Oslo, Norway, 23 August 2017: Photocure ASA (OSE:PHO), today reported a Hexvix/Cysview revenue growth of 10% to NOK 37.6 million in the second quarter of 2017 (Q2 2016: NOK 34.2), with an EBITDA of...
Photocure ASA: Blue Light Cystoscopy with Hexvix® reduces recurrence rate at 3 years in real-life experience study
18. August 2017 02:47 ET
|
Photocure ASA
Oslo, Norway, August 18, 2017: Photocure ASA (OSE: PHO) today announced that a prospective controlled study investigating the introduction of Blue Light Cystoscopy (BLC(TM)) with Hexvix® at first...